Human CD19-CD22 Targeted T Cells not checked
Hrain Biotechnology Co., Ltd. · CD19-CD22 CAR-T
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.”In the company’s words, NCT05223686 on ClinicalTrials.gov
- Tested for
- Acute Lymphoblastic Leukemia
- Main trialPhase 1
- “To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19-CD22 CAR+ T cells.”In the company’s words, NCT05223686 on ClinicalTrials.gov
- Other names
- CD19-CD22 CAR-T
Other drugs for Acute Lymphoblastic Leukemia
- TisagenlecleucelNovartis · Phase 3
- VenetoclaxAbbVie · Phase 3
- RemimazolamAcacia Pharma Ltd · Phase 2/3
- BlinatumomabAmgen · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Orca-TOrca Biosystems, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 10 Jun 2023 | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026